The present study of adaptive processes in the central cholinergic system was motivated by the use of AChE inhibitors in human disease, primarily for the treatment of dementias such as Alzheimer ́s disease (AD) [19,20]. This evidence concerns the gene ACHE and early-onset autosomal dominant Alzheimer disease.